KLTO and Japan’s Okinawa Research Center for Longevity Science partner to assess alpha-Klotho protein levels in centenarian blood and tissues, investigating how declining expression correlates with age-related pathologies. By leveraging gene therapy to restore secreted Klotho isoform, they aim to mitigate neurological disorders and extend healthspan in humans, building on promising preclinical models.
Key points
- Quantification of alpha-Klotho and s-KL levels in centenarian blood and tissue via immunoassays.
- AAV-mediated s-KL gene therapy vectors designed to restore secreted Klotho expression and evaluate neuroprotective efficacy.
- Correlation analysis between s-KL depletion and onset of ALS, Alzheimer’s, and Parkinson’s, highlighting biomarker and therapeutic potential.
Why it matters: Restoring Klotho levels offers a novel therapeutic strategy to counteract age-related neurodegeneration and extend human healthspan.
Q&A
- What is alpha-Klotho?
- What is the secreted Klotho isoform?
- How is Klotho gene therapy delivered?
- Why study Okinawan centenarians?